Lilly To Cease Development of Phase III Alzheimer's Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The setback for semagacestat is yet another blow Lilly can ill afford as it aims to scale its patent cliff. It could also signal trouble for an entire class of related therapies.
You may also be interested in...
No Big Surprises From Lilly: Management Sticks To Its Guns On Strategy
With the loss of Zyprexa just months away, Eli Lilly management sought to reassure investors its strategy of focusing on its internal pipeline and core growth areas will pay off post-2014.
No Big Surprises From Lilly: Management Sticks To Its Guns On Strategy
With the loss of Zyprexa just months away, Eli Lilly management sought to reassure investors its strategy of focusing on its internal pipeline and core growth areas will pay off post-2014.
On Q3 Earnings Call, Lilly Vows To Stay Its Current Course Despite Late-Stage Pipeline Setbacks
As analysts call for transformative M&A, executives talked up Lilly's modest diversification efforts, including its animal health business, Elanco, and strong Japanese sales.